D-dimer levels in patients with chronic urticaria: A case-control study on a Kashmiri population

Uzair Khursheed, Shuhaab Shah, Aaqib Aslam, Javeed Sultan, Faizan Younus, Shagufta Rather

Department of Dermatology, Government Medical College, Srinagar, University of Kashmir, Jammu and Kashmir, India

Corresponding author: Aaqib Aslam, MD, E-mail: shahaaqib2010@gmail.com

How to cite this article: Khursheed U, Shah S, Aslam A, Sultan J, Younus F, Rather S. D-dimer levels in patients with chronic urticaria: A case-control study on a Kashmiri population. Our Dermatol Online. 2022;13(4):365-367.
Submission: 06.04.2022; Acceptance: 24.07.2022

DOI: 10.7241/ourd.20224.4

Citation tools: 

Related Content

Copyright information
© Our Dermatology Online 2022. No commercial re-use. See rights and permissions. Published by Our Dermatology Online.


Background: Chronic urticaria (CU) is a common skin condition, affecting 0.5-1% of the population. Multiple studies have demonstrated that plasma D-dimer levels could be employed as a biomarker for disease activity and treatment response in patients with CU.

Aim: The aim was to evaluate the correlation between D-dimer levels and the disease activity of CU.

Materials and Methods: This study was a case-control study conducted on 120 patients suffering from CU and 50 healthy subjects. Plasma D-dimer levels were measured using ELISA.

Results: Mean plasma D-dimer levels in the patients with CU (720.5 ng/mL) were significantly higher than those in the controls (405.6 ng/mL) (p < 0.001). A significant correlation was observed between plasma D-dimer levels and the UAS (urticaria activity score).

Conclusion: The patients with CU had higher plasma D-dimer levels than the control group. A positive statistical correlation was observed between plasma D-dimer levels and the severity of CU.

Key words: Chronic urticaria; D-dimer; Autoimmunity


Chronic urticaria (CU) is a pruritic skin condition characterized by wheals and/or angioedema lasting for at least six weeks or longer [1]. It is a common cause in patients presenting to primary care, emergency rooms, and dermatologists [2]. With a point prevalence of 0.5-1% in the population, it is one of the most common skin disorders encountered [3].

Chronic urticaria may severely affect the quality of life of the patient, due to the duration of symptoms, which may persist for years [4]. Nearly half of the patients have persistent symptoms even after three years of onset [5].

The release of histamine and other inflammatory mediators from mast cells causes an acute inflammatory response, including vasodilatation, increased fluid permeability, and the recruitment of various cells, which constitute the basic pathogenesis of the disease [1].

In CU, autoimmunity plays a major role. In a subset of patients, the coagulation cascade is also activated through the extrinsic pathway, which may increase plasma D-dimer levels [6,7].

Recent studies have demonstrated the correlation between plasma D-dimer levels and CU, suggesting the possibility of the use of plasma D-dimer levels as a biomarker for disease activity and response to treatment in patients with CU [811].

There is a paucity of data concerning plasma D-dimer levels in Kashmiri patients with CU. This study investigates the relationship between plasma D-dimer levels and disease activity in a Kashmiri population.


This study was conducted after receiving clearance from the institutional ethical committee. A total of 120 patients with CU (more than two episodes a week for more than six weeks) who visited the outpatient department of dermatology of the Government Medical College in Srinagar, India, from November 2020 to July 2021, aged at least eighteen years, and clinically diagnosed with CU were included in the study. Patients with diseases or taking medications that could have altered the coagulation pathways were excluded from the study.

A total of fifty age- and sex-matched healthy subjects undergoing routine check-ups comprised the control group.

All cases and controls voluntarily agreed to participate in the study and signed a written consent form. Demographic data and personal, family, and medical histories were recorded.

Assessment of Disease Activity

All patients were interviewed by a dermatologist and the urticaria activity score (UAS) was determined. Disease activity was assessed on the basis of the EAACI/GA2LEN/EDF activity score [1], comprising the wheal score and pruritis score. Disease activity was scored from 0 to 6, where 0 was considered no disease, 1-2 mild disease, 3-4 moderate, and 5-6 severe.


Plasma D-dimer levels were measured using the ELISA (enzyme-linked immunosorbent assay) in accordance with the manufacturer’s recommendations (Instrumentation Laboratory Company, Bedford, MA, 01730-2443 (U.S.)). Levels below 500 ng/mL were regarded as normal.

Statistical Analysis

The data was analyzed with the SPSS software. Descriptive statistics and percentages were used to describe the demographic data, clinical features, and plasma D-dimer levels. Non-parametric tests (e.g., chi-squared test) were employed to evaluate differences between the groups. Correlation was calculated using Spearman’s rank test and logistic regression analysis. The statistical significance at p < 0.05.


Demographic and Clinical Characteristics

Out of the 120 patients, 52 were males (43.3%) and 68 were females (56.7%), with a mean age of 33.5 ± 8.4 years. The average age of onset was 31.5 ± 8 years. The duration of disease in the majority of the patients was ≤ 1 year with a mean duration of 15 months. Out of the 120 patients, 29 (24%) had associated angioedema, whereas 15 (12.5%) had a family history of atopy (asthma, allergic rhinitis, etc.). A majority of the patients (56; 46.6%) had moderate disease severity, 41 (34%) had mild severity, and 14 (11.6%) had severe severity. Nine patients had the disease well under control.

Correlation between Plasma D-Dimer Levels and Disease Severity

The patients were divided into three groups: < 1 year, 1-5 years, and > 5 years. It was noted that D-dimer levels in patients who had a longer duration of the disease were significantly higher (p < 0.05).

The difference in the proportion of abnormal plasma D-dimer levels in the patients with CU and the control group was statistically significant (60.8% vs. 44%; p = 0.04) (chi-squared test: 4.05). Plasma D-dimer levels were significantly higher in the patients with CU than in the control group (720.5 ng/mL vs. 405.6 ng/mL; p < 0.001). Table 1 shows disease severity and plasma D-dimer levels among all groups.

Table 1: Disease severity and plasma D-dimer levels among all groups.


It is imperative to find reliable biomarkers to assess disease severity when determining the correlation between disease severity and treatment response. A study by Raffael et al. [11] found that disease severity may also predict the duration of chronic spontaneous urticaria.

Studies have shown a link in the pathogenesis of CU with the activation of the coagulation cascade [7,12,13]. The activation of this cascade results in thrombin formation and the activation of mast cells. This leads to the release of histamine from mast cells and causes edema formation in urticaria [7]. D-dimer, which is an FDP (fibrin degradation product) is formed after the lysis of thrombus. It may remain elevated in the serum for around one week [14].

In our study, we observed higher D-dimer levels in the patients with CU than in the control group. Similar results were found in other studies conducted in other regions [8,10,14]. Thus, our study provides further evidence of a possible mechanism of coagulation cascade activation in patients with CU.

Our study demonstrated statistically higher plasma D-dimer levels and a higher proportion of abnormal plasma D-dimer levels in patients with CU. This was corroborated in a study by Asero et al. [15]. This finding is also supported by a literature review by Pavel et al. [16].

D-dimer levels and CRP show a strong correlation with CSU activity [16]. Our study also found a positive correlation between disease severity and serum D-dimer levels. Hence, D-dimer may play a vital role as a biomarker for CU severity. Besides, D-dimer levels in the plasma may also be employed to assess treatment response and potential antihistamine resistance to CU [17]. Therefore, D-dimer may be a predictor of response to treatment, more so in refractory cases or antihistamine-resistant CU.

Although several studies show a possible correlation between plasma D-dimer levels and CU, larger studies are needed due to the lack of strong evidence.


The following limitations were noted in this study:


  1. The correlation between D-dimer levels and treatment response was not assessed.
  2. Other biomarkers were not assessed.



In our study, the patients with CU had higher plasma D-dimer levels than the control subjects, and the levels of D-dimer were higher in more severe cases. D-dimer levels may be considered a biomarker for disease activity/severity.

Statement of Human and Animal Rights

All the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the 2008 revision of the Declaration of Helsinki of 1975.

Statement of Informed Consent

Informed consent for participation in this study was obtained from all patients.


1. Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B, et al. The EAACI/GA (2) LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73:1393-414.

2. Grattan CEH, Saini SS. Urticaria and Angioedema. In:Bolognia JL, Schaffer JV, Cerroni L, editors. Dermatology. 4th edn. New York:Elsevier;2018. pp. 304-19.

3. Weller K, Altrichter S, Ardelean E. Chronic urticaria:Prevalence, course, prognostic factors and impact. Hautarzt. 2010;61:750-7.

4. Dias GA, Pires GV, Valle SO. Impact of chronic urticaria on the quality of life of patients followed up at a university hospital. An Bras Dermatol. 2016;91:754-9.

5. Sadowska B, Sztormowska M, Gawinowska M, Chelminska M. Sodium metabisulfite hypersensitivity in urticaria. Our Dermatol Online. 2021;12:106-12.

6. Kolkhir P, Borzova E, Grattan C, Asero R, Pogorelov D, Maurer M. Autoimmune comorbidity in chronic spontaneous urticaria:A systematic review. Autoimmun Rev. 2017;16:1196-208.

7. Yanase Y, Takahagi S, Hide M. Chronic spontaneous urticaria and the extrinsic coagulation system. Allergol Int. 2018;67:191-4.

8. Nguyen HT, Vu TTP. Plasma D-dimer level in Vietnamese patients with chronic urticaria. Indian J Dermatol. 2021;66:496-500.

9. Ghazanfar MN, Thomsen SF. D-dimer as a potential blood biomarker for disease activity and treatment response in chronic urticaria:A focused review. Eur J Dermatol. 2018;28:731-5.

10. Triwongwaranat D, Kulthanan K, Chularojanamontri L, Pinkaew S. Correlation between plasma D-dimer levels and the severity of patients with chronic urticaria. Asia Pac Allergy. 2013;3:100-5.

11. Rabelo-Filardia R, Daltro-Oliveiraa R, Campos RA. Parameters associated with chronic spontaneous urticaria duration and severity:A systematic review. Int Arch Allergy Immunol. 2013;161:197-204.

12. Takeda T, Sakurai Y, Takahagi S, Kato J, Yoshida K, Yoshioka A, et al. Increase of coagulation potential in chronic spontaneous urticaria. Allergy. 2011;66:428-33.

13. Teclessou JN, Atsou K, Kombate K, Gnossike P, Akakpo AS, Mouhari-Toure A, et al. [Chronic urticaria in dermatology in Lomé:Study of 129 cases]. Our Dermatol Online. 2021;12(Supp. 1):1-5.

14. Takeda T, Sakurai Y, Takahagi S, Kato J, Yoshida K, Yoshioka A, et al. Increase of coagulation potential in chronic spontaneous urticaria. Allergy. 2011;66:428-33.

15. Asero R, Marzano AV, Ferrucci S, Cugno M. D-dimer plasma levels parallel the clinical response to omalizumab in patients with severe chronic spontaneous urticaria. Int Arch Allergy Immunol. 2017;172:40-4.

16. Kolkhir P, AndréF, Church MK, Maurer M, Metz M. Potential blood biomarkers in chronic spontaneous urticaria. Clin Exp Allergy. 2017;47:19-36.

17. Asero R. D-dimer:A biomarker for antihistamine-resistant chronic urticaria. J Allergy Clin Immunol. 2013;132:983-6.


Source of Support: Nil,

Conflict of Interest: The authors have no conflict of interest to declare.

Request permissions
If you wish to reuse any or all of this article please use the e-mail (brzezoo77@yahoo.com) to contact with publisher.

Related Content:

Related Articles Search Authors in


Comments are closed.